


La recherche biomédicale : au carrefour des nouveaux partenariats

JY Blay
Lyon, EORTC



Traitements ciblés?

- CD20, CD33
- ER, PgR, AR
- VEGF, IL-6
- HER2
- EGFR
- bcr-abl
- KIT
- VEGFR
- MEK...



2010: Oncologie moléculaire

■ Trouver la cible

□ Anomalie moléculaire « initiale »

» Bcr-abl, KIT, PDGFA, PDGFRA, CSF1, TSC, HER1, translocations

□ Anomalie moléculaire « secondaire »

» VEGF/VEGFR2, mTOR...

Comment identifier la cible?

Expression → Possible target

Expression + Activation → Promising target

Expression + Activation + Mechanism → A major target


Expression + Activation + Mechanism + Drug → Clinical trial

J. Fletcher, Sarcoma “State of the Science” Meeting, 17 June 2002, Bethesda, MD, USA

Conséquences pratiques


- Fragmentation des tumeurs fréquentes
 - Sous groupes plus homogènes sur le plan mutationnel, mais faible fréquence
 - ▶ e.g. NSCLC: HER1, Alk
- Diagnostic moléculaire
- Etudes cliniques intergroupe/internationales
- Groupes académiques indépendants

EORTC




- DDN 1962
- Académique
- Headquarters: Brussels, 170 personnes
- Clinical and Laboratory research divisions
- Groupes cliniques et précliniques

EORTC global strategy (1)



- Academic organization
- Large scale clinical trials
- Strategic therapeutic questions
 - Influence medical practice
 - Improve the understanding of the disease
- Multidisciplinary approach
 - Principal strength of the EORTC
 - Involve pathologists and laboratory scientists
 - Integrate translational research into clinical trials

EORTC strategy (2)



- Molecular clinical trials
 - Translational research
- “NOCI” (Network of Core Institutions):
 - a network conducting high quality tailored treatment investigations.
 - Consortium agreement with 26 centers
- New models of collaboration with national and multinational academic groups :
 - EORTC HQ as a platform for collaboration in trials from national groups or other international academic partners :
Academic Research Organisations
- Specificity for niche indications



Futur

- Multidisciplinarité
- Qualité et efficacité des essais
- Collaborations internationales EU +
- Interactions avec industrie pharmaceutique
- Recherche académique forte
- Directive EU